Baseline variables of patients
| Variables | Aspirin (n=230) | DAPT (n=215) | Intravenous t-PA (n=385) | P value |
| Age (years), median (IQR) | 62.2 (54.8–72.2) | 63.8 (55.2–71.2) | 61.0 (54.0–69.0) | 0.10 |
| Sex, male (%) | 149 (64.8) | 149 (69.3) | 257 (66.8) | 0.60 |
| Medical history (%) | ||||
| Smoking | 97 (42.2) | 87 (40.5) | 157 (40.8) | 0.92 |
| Independence (mRS 0–1) prior to stroke | 177 (77.0) | 175 (81.4) | 334 (86.8) | 0.007 |
| Atrial fibrillation | 11 (4.8) | 12 (5.6) | 17 (4.4) | 0.81 |
| Hypertension | 137 (57.8) | 135 (62.8) | 252 (65.5) | 0.34 |
| Diabetes mellitus | 43 (18.7) | 52 (24.2) | 77 (20.0) | 0.32 |
| Hyperlipidaemia | 21 (9.1) | 22 (10.2) | 35 (9.1) | 0.89 |
| *Previous stroke | 51 (22.2) | 42 (19.5) | 65 (16.9) | 0.26 |
| Previous TIA | 4 (1.7) | 7 (3.3) | 14 (3.6) | 0.40 |
| Median blood glucose (mmol/L) | 5.3 (4.9–6.1) | 5.7 (4.9–6.9) | 5.6 (4.9–7.0) | 0.02 |
| Systolic blood pressure (mm Hg) | 150±23.1 | 151.5±21.3 | 152.7±20.4 | 0.16 |
| Diastolic blood pressure (mm Hg) | 88.9±13.3 | 88.5±12.2 | 87.5±12.4 | 0.35 |
| Weight (kg) | 67.9±9.7 | 70.1±9.8 | 68.9±11.5 | 0.07 |
| Median NIHSS score (IQR) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 0.97 |
| Median stroke onset to treatment time (IQR) (hours) | 3.5 (2.6–4.0) | 3.5 (2.5–4.0) | 2.9 (2.2–3.6) | <0.001 |
Data were presented as median (IQR) for continuous and ordinal variables, and number of patients/total number from whom data were available (%) for categorical variables.
*The previous stroke of patients in the CHANCE study was ischaemic stroke, while it was ischaemic and haemorrhagic stroke in the intravenous t-PA group.
CHANCE, Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack; DAPT, dual antiplatelet therapy; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; TIA, transient ischaemic attack; t-PA, tissue plasminogen activator.